Clinical Trials
10 trialsNCT06239298 2024-06-14
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT02489201 2023-06-15
A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Terminated
NCT02489214 2023-05-08
Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Terminated
NCT02698111 2023-05-08
Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Terminated
NCT04402723 2022-12-01
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Terminated
NCT02870582 2022-11-29
Donafenib for Previously Treated Metastatic Colorectal Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Completed
NCT04472858 2022-11-29
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Unknown
NCT03602495 2021-12-13
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Terminated
NCT02870569 2019-03-01
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Completed
NCT02489916 2016-01-05
Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Completed